Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms
Abstract
Clusterin is suggested to be involved in the pathogenesis of Alzheimer's disease. Clusterin expression is increased in brain tissue in affected regions of Alzheimer patients, and intense clusterin staining is found in both senile plaques and in neuronal and glia cells. In contrast, the cerebrospinal fluid level of clusterin in Alzheimer patients has, thus far, been found unchanged. Clusterin is a glycosylated protein, and an alteration of its glycosylation in Alzheimer's disease might influence accurate quantification in cerebrospinal fluid through interference of antibody binding to the protein. Using enzymatic deglycosylation of clusterin isolated from cerebrospinal fluid, we found that the carbohydrates attached to clusterin were of the N-linked type and sialic acids. Based on this finding, cerebrospinal fluid samples from Alzheimer patients (n=99) and controls (n=39) were analysed. The samples were treated with peptide: N-glycanase F, cleaving off N-linked carbohydrates, and clusterin was quantified before and after deglycosylation using a new sandwich enzyme-linked immunosorbent assay. Clusterin was significantly increased in Alzheimer patients, in both native (7.17+/-2.43 AU versus 5.73+/-2.09 AU; p=0.002), and deglycosylated samples (12.19+/-5.00 AU versus 9.68+/-4.38 AU; p=0.004). Deglycosylation led to increased measured levels of clusterin by 70% (p<0.001) in Alzheimer patients and 67% (p<0.001) in controls. These findings indicate that glycosylation of proteins may interfere with their quantification. The results show that clusterin is significantly increased in cerebrospinal fluid from Alzheimer patients as a group, supporting that clusterin might be involved in the pathogenesis of Alzheimer's disease. However, the individual clusterin levels overlap between the two groups, and thus cerebrospinal fluid clusterin measurement is not suitable as a biochemical marker in the diagnosis of Alzheimer's disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A previous study found that CSF clusterin levels were significantly higher in Alzheimer's disease patients than controls.
“In a previous study of 99 patients and 39 controls CSF levels of CLU were significantly higher in AD patients (p=0.002) (Nilselid, et al., 2006)”
From A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin (2016) · cites this paper as Nilselid, et al., 2006
Elevated CSF clusterin levels have been observed in Alzheimer's disease patients.
“and elevated CSF CLU levels have been observed in AD patients (Nilselid, et al., 2006)”
From A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin (2016) · cites this paper as Nilselid, et al., 2006
The citation lists haven’t been fetched yet
References 52 · Cited by 104
- Authors
- Nilselid, A.-M., Davidsson, P., Nägga, K., Andreasen, N., Fredman, P., & Blennow, K.
- Affiliations
- Sahlgrenska University Hospital (SE)
- AstraZeneca (Sweden) (SE)
- Linköping University Hospital (SE)
- Karolinska University Hospital (SE)
- Corresponding author
- Nilselid, A.-M.
- Venue
- Neurochemistry International
- Publisher
- Elsevier BV
- Published
- 2006-06
- Volume
- 48
- Issue
- 8
- Pages
- 718-728
- ISSN
- 0197-0186 (ISSN-L)
- OpenAlex
- W2063157384
- Cited by
- 104
- References
- 52
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 3 · 2023: 8 · 2022: 6 · 2021: 9 · 2020: 6 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 5 · 2015: 10 · 2014: 8 · 2013: 8 · 2012: 11
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurochemistry International (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Health Sciences › Medicine › Oncology › Clusterin in disease pathology
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- clusterin, cerebrospinal fluid, Alzheimer's disease, glycosylation, N-linked carbohydrates, sialic acid, deglycosylation, sandwich ELISA, biomarkers
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Antibody Specificity, Brain, Carbohydrates, Enzyme-Linked Immunosorbent Assay, Female, Glycosylation, Humans, Male, Predictive Value of Tests, Protein Binding, Biomarkers, Up-Regulation, Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase, Clusterin, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review